PEB - Pacific Edge Ltd

[steve06]

was doing some catch up reading last night, came across this http://effectivehealthcare.ahrq.gov/...col-140721.pdf

looks like Cxbladder has a few more competitors than I thought (There are five diagnostic biomarker tests approved by the FDA for diagnosis or surveillance of bladder cancer: BTAstat® (BTA), Alere NMP22®, BladderChek® (NMP22), UroVysion® (FISH) and ImmunoCyt™), does anyone know how extensive these tests are used in the US, or how well performance wise these tests are?

[steve06]

Been hectic with work and other commitments so haven't had the time to do more in-depth research...

[psychic]

was doing some catch up reading last night, came across this http://effectivehealthcare.ahrq.gov/...col-140721.pdf

looks like Cxbladder has a few more competitors than I thought (There are five diagnostic biomarker tests approved by the FDA for diagnosis or surveillance of bladder cancer: BTAstat® (BTA), Alere NMP22®, BladderChek® (NMP22), UroVysion® (FISH) and ImmunoCyt™), does anyone know how extensive these tests are used in the US, or how well performance wise these tests are?

The Edison report provides an overview:

http://www.edisoninvestmentresearch....CT=18&ID=12799

[Crystal Ball]

was doing some catch up reading last night, came across this http://effectivehealthcare.ahrq.gov/...col-140721.pdf

looks like Cxbladder has a few more competitors than I thought (There are five diagnostic biomarker tests approved by the FDA for diagnosis or surveillance of bladder cancer: BTAstat® (BTA), Alere NMP22®, BladderChek® (NMP22), UroVysion® (FISH) and ImmunoCyt™), does anyone know how extensive these tests are used in the US, or how well performance wise these tests are?

Hi steve06, according to the Edison report, yes there are several other companies in the melting pot however Pacific Edge in their words have a leg up on the opposition in that they are far more ahead and advanced than their competitors....

[Crystal Ball]

was doing some catch up reading last night, came across this http://effectivehealthcare.ahrq.gov/...col-140721.pdf

looks like Cxbladder has a few more competitors than I thought (There are five diagnostic biomarker tests approved by the FDA for diagnosis or surveillance of bladder cancer: BTAstat® (BTA), Alere NMP22®, BladderChek® (NMP22), UroVysion® (FISH) and ImmunoCyt™), does anyone know how extensive these tests are used in the US, or how well performance wise these tests are?

Hi steve06, according to the Edison report, yes there are several other companies in the melting pot however Pacific Edge in their words have a leg up on the opposition in that they are far more ahead and advanced than their competitors....

[steve06]

I've come across these two (mid to small sized) studies previously, carried out in Australiasia?, have they recently completed studies of regional US populations or representative US populations? As gene variances are found across populations, different races of people, regions etc, one test which proves useful in one population might not be so useful in another...

[skid]

Another question may be -have any of the tests that have been around for a while been successful?(if one product has been successful-then it stands to reason that another better one, would be MORE successful--But if none have been successful,then it is an unproven market.

[skid]

Sold at ~$0.82. Remainders at $0.80 dropping the price to that.
Pretty 50/50 decision. Dunno whether it was the good one, might buy again soon.

You are being very prudent Klid which is commendable(a bird in the hand,and all that)

Here's a quote from a pretty clued in poster(IMO)

Buying stocks is easy. Its the selling of them thats hard! The toughest lesson to learn is when to sell a share (goes on to explain how dangerous it is when a share's 50day moving average is below the 200 day ma---all about uptrends and downtrends)

[psychic]

I've come across these two (mid to small sized) studies previously, carried out in Australiasia?, have they recently completed studies of regional US populations or representative US populations? As gene variances are found across populations, different races of people, regions etc, one test which proves useful in one population might not be so useful in another...

It's a good question Steve06 and I don't know if it has been discussed here. My understanding is that CxBladder identifies changes in gene expression (5 markers) and so useful across the board. Is it the genetic propensity to develop Bladder Cancer that may vary? Hopefully Hancocks or someone better informed will let us know.


cheers

[psychic]

Another question may be -have any of the tests that have been around for a while been successful?(if one product has been successful-then it stands to reason that another better one, would be MORE successful--But if none have been successful,then it is an unproven market.

Yes they are, and big money is involved.They have been adopted in practice but fall short on performance